AlzeCure Pharma
25.8.2021 09:02:06 CEST | ACCESS Newswire | Press release
STOCKHOLM, SE / ACCESSWIRE / August 25, 2021 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6)
AlzeCure Pharma AB (publ) (FN STO: ALZCUR) today announced that its interim report for the period January - June 2021 is now available on the company's website: www.alzecurepharma.se/en/section/investors/financial-reports/
"The AlzeCure team continues to make good progress according to plan, in high-profile areas that are becoming increasingly relevant, such as the US Food and Drug Administration's (FDA) approval of a new drug for Alzheimer's disease, the first in 18 years, which is expected to boost interest in the Alzheimer's field. During the second quarter, we communicated positive data from our Phase Ib clinical trial of ACD440 for neuropathic pain and are now preparing for a Phase II trial and a pre-IND meeting with the FDA. We also focused on running the Phase I clinical trial for ACD856 in Alzheimer's disease and on further developing compounds in our preclinical pain project, TrkA-NAM, with the aim of choosing a drug candidate for the project in the second half of 2021. Thus we have once again closed the books on yet another positive and very active quarter at AlzeCure."
Martin Jönsson, CEO
Financial information for April - June, 2021
Figures in parentheses refer to the corresponding period of the previous year.
- Net sales during the period totaled SEK 0 thousand (0).
- Loss for the period totaled SEK -15,693 thousand (-18,407).
- Earnings per share, basic, totaled SEK -0.42 (-0.49).
- Total assets at the end of the period amounted to SEK 82,030 thousand (160,057).
- Cash and cash equivalents at the end of the period totaled SEK 77,915 thousand (153,325).
Financial information for January - June, 2021
Figures in parentheses refer to the corresponding period of the previous year.
- Net sales during the period totaled SEK 0 thousand (0).
- Loss for the period totaled SEK -38,655 thousand (-32,191).
- Earnings per share, basic, totaled SEK -1.02 (-0.85).
- Total assets at the end of the period amounted to SEK 82,030 thousand (160,057).
- Cash and cash equivalents at the end of the period totaled SEK 77,915 thousand (153,325).
Significant events during the period January - March, 2021
- The company appointed Märta Segerdahl Storck, MD/PhD, to serve as Chief Medical Officer (CMO). Märta took up the position on April 1 and is responsible for our clinical development activities. She is also part of AlzeCure's management group.
Significant events during the period April - June, 2021
- On April 19 the company received, slightly ahead of plan, positive and significant efficacy data from the phase Ib clinical trial with the drug candidate ACD440 for neuropathic pain. It was also well tolerated as a topical treatment.
- Eva Lilienberg was elected to serve on AlzeCure's Board of Directors at the Annual General Meeting on May 17. Eva further strengthens the company with her broad international regulatory and commercial experience.
Significant events after the end of the period
- No significant events have occurred after the end of the period.
The full report is attached as PDF and is available on the company's website: www.alzecurepharma.se/en/section/investors/financial-reports/
For more information, please contact
Martin Jönsson, CEO
Tel: +46 707 86 94 43
martin.jonsson@alzecurepharma.com
About AlzeCure Pharma AB (publ)
AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.
NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease and comprises two drug candidates. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development to an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies.
Contact:
FNCA Sweden AB, +46(0)8 528 00 399 info@fnca.se, is the company's Certified Adviser. For more information, please visit www.alzecurepharma.se.
Attachments
SOURCE: AlzeCure Pharma
View source version on accesswire.com:
https://www.accesswire.com/661270/AlzeCure-Publishes-its-Interim-Report-for-January-June-2021
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Chervon Promotes Soobia Haroon to Vice President, Human Resources - NA2.11.2026 15:00:00 CET | Press release
NAPERVILLE, IL / ACCESS Newswire / November 2, 2026 / Chervon promotes Soobia Haroon to Vice President, Human Resources - NA, effective November 2, 2026, reporting to Joe Galli, CEO. Over the past two years, Haroon has been a key member of the Chervon Senior Executive Team, driving talent acquisition, organizational development, and transformation. She has provided strategic leadership across all HR functions while strengthening corporate HR strategy, governance, and processes to support the company's objectives and continued growth. Before joining Chervon, Soobia progressed through a series of human resources positions at several multinational companies. Her HR experience is strong in supporting many functional areas, including supply chain, distribution, manufacturing, IT, engineering, product management, marketing, and finance. "Soobia has been instrumental in our aggressive talent acquisition initiative since I joined Chervon," said Joe Galli. "Her extensive HR experience, her sens
Chervon Names Thomas Scherer Vice President of Organizational Development - Sales, End User Marketing, and Service2.11.2026 15:00:00 CET | Press release
NAPERVILLE, IL / ACCESS Newswire / November 2, 2026 / Chervon names Thomas Scherer Vice President of Organizational Development - Sales, End User Marketing, and Service, effective November 2, 2026, reporting to Matt DeFeo, SVP, Sales, Training, and Recruiting. Scherer brings to Chervon extensive organizational development experience supporting the build-out of large-scale sales teams and end user marketing teams. He is highly experienced in managing employment law, compliance, employee relations, compensation, workforce analytics, training, recruiting, and career development. His world class organizational development skills will be invaluable as the company develops the very best sales, store coverage, end user marketing, and after-sales service teams. Most recently, Tom was Vice President of Human Resources for TTI/Milwaukee where he was responsible for HR and organizational development for a 2000+ person field sales team. Previously, Scherer advanced through a series of HR, training
Chervon Names Jody Grimsley Senior National Account Manager2.11.2026 15:00:00 CET | Press release
NAPERVILLE, IL / ACCESS Newswire / November 2, 2026 / Jody Grimsley joins Chervon as Senior National Account Manager, effective November 2, 2026, reporting to Jeff Campbell, SVP of Industrial Commercial Sales. In his new role, Grimsley will focus on developing key strategic relationships with commercial landscape dealers, driving growth of the EGO Commercial OPE range. Jody brings 17+ years of commercial sales experience at TTI/Milwaukee. His outstanding sales growth performance included building significant businesses in the Transportation Channel and Hardware Channel. Earlier in his career, he excelled through sales roles of increasing complexity and as a Regional Sales Manager in the Industrial Channel. "Jody brings a strong track record of developing strategic relationships, driving outstanding sales growth and building successful sales organizations," said Jeff Campbell. "His extensive key account experience and his customer-centric approach will be invaluable as we build our busi
Hydrosat Announces Nyktòs Program to Provide Tactical ISR for Sovereign Customers from New Facility in Europe2.11.2026 12:00:00 CET | Press release
LUXEMBOURG, LU / ACCESS Newswire / November 2, 2026 / Hydrosat, the leading provider of thermal infrared satellite solutions, announced today its high-resolution mid-wave infrared (MWIR) program named Nyktòs. Nyktòs will deliver high-resolution thermal imaging for tactical ISR. The day-and-night imaging capability can be tasked by customers and is complementary to the wide-area monitoring provided by Hydrosat's Osiris constellation. The development of the new capability will be supported by Hydrosat's expanded technology and manufacturing footprint in Europe and is intended for sovereign mission applications for NATO and allied customers. As part of the expansion, Hydrosat will open additional facilities, grow its network of European supply chain partners and advance the development of high-resolution mid-wave infrared technology in the region. Together, these investments will strengthen the company's ability to support sovereign government and allied missions across national security,
Aer Lingus and MTech Mobility Launch Live Ground Operations Technology Programme Across Three Irish Airports2.11.2026 11:00:00 CET | Press release
WEXFORD, IRELAND / ACCESS Newswire / November 2, 2026 / Aer Lingus and MTech Mobility have launched a new mobility-based hands-free scanning and communications solution across below-the-wing ground operations at Dublin, Cork, and Shannon airports. The programme is fully live at all three locations. The programme was built around three operational goals Aer Lingus set out to achieve: faster, more accurate baggage scanning that keeps handlers' hands free to move luggage; a single device that works as both a scanning tool and a real-time communications channel for ground teams; and personal device ownership for staff, ending the long-standing problem of shared equipment going missing between shifts. "Our ground teams work in one of the most demanding environments in the business. Our focus at Aer Lingus is operational resilience, efficiency, and consistency, and we needed a partner who understood that before they proposed a solution - one who would own the programme from day one, not just
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom